BCLI — Brainstorm Cell Therapeutics Share News
0.000.00%
Last trade - 00:00US FDA panel votes against BrainStorm's ALS therapy
Brief: Brainstorm Cell Therapeutics Inc Says FDA Advisory Committee (Meeting To Review Nurown For Als
What to Watch in the Day Ahead - Wednesday, September 27
U.S. STOCKS ON THE MOVE-Starbucks, Williams-Sonoma, FedEx
U.S. STOCKS ON THE MOVE-Soligenix, Enovis, Lifeway Foods
BrainStorm Cell falls on FDA concerns over ALS therapy
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (updated)
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
Brainstorm Cell Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brainstorm Cell Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Brainstorm Cell Therapeutics Announces Pricing Of $7.5 Mln Registered Direct Offering
Brief: Brainstorm Cell Therapeutics Appoints Executive Vice President And Chief Development Officer
Brief: Brainstorm Cell Therapeutics Data Show Treatment With NurOwn Significantly Reduces NfL, A Key Biomarker Of Neurodegeneration
U.S. STOCKS ON THE MOVE-Cenovus Energy, Compass Pathways,
U.S. STOCKS ON THE MOVE-NovoCure, Intuit, Splash Beverage
U.S. STOCKS ON THE MOVE-TScan Therapeutics, Palantir, Coinbase Global
U.S. STOCKS ON THE MOVE-Energy firms, GitLab, BrainStorm
BrainStorm rises as FDA panel to review ALS therapy in Sept
Brief: Brainstorm Cell Therapeutics Announces FDA Advisory Committee Meeting To Review Nurown Biologics License Application